

## **Massachusetts General Hospital Begins Recruiting for Stroke Study**

*Joins University of Maryland hospital in drug trial aimed at patients with severe ischemic stroke who are likely to experience clinically significant brain swelling.*

New York, NY, USA – June 6, 2011 – Remedy Pharmaceuticals, Inc. today announced that the GAMES-PILOT study of RP-1127 in severe stroke will begin recruiting patients at Massachusetts General Hospital.

GAMES-PILOT is a multi-center, prospective, open label, Phase 2a trial of RP-1127 in patients with a severe ischemic stroke who are likely to experience clinically significant brain swelling, termed malignant infarction. Malignant infarction is the syndrome of a large stroke causing progressive edema and tissue swelling that compromises arterial inflow to surrounding tissues, culminating in further ischemic damage, enlargement of the infarct, herniation, and death.

The study is already enrolling at the University of Maryland Medical Center. It is anticipated that the information gained in GAMES-PILOT will assist the Company in developing a larger randomized, double-blinded study it has planned for this patient population.

The site Principal Investigator for Massachusetts General Hospital is W. Taylor Kimberly, MD. Dr. Kimberly is an associate director, Massachusetts General Hospital Neuroscience Intensive Care Unit and an Instructor in Neurology at Harvard Medical School.

"The addition of Massachusetts General Hospital further validates the importance of the GAMES-PILOT study," says Sven Jacobson, Chief Executive Officer of Remedy. "We are thrilled to have them on board and look forward to their participation in this ground-breaking study."

Detailed information for this study is available at:  
<http://clinicaltrials.gov/ct2/show/NCT01268683>

### **About RP-1127**

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of  $NC_{Ca-ATP}$  channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

## **About Remedy Pharmaceuticals**

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: [info@remedypharmaceuticals.com](mailto:info@remedypharmaceuticals.com)